Free Trial
NASDAQ:NMRA

Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Neumora Therapeutics logo
$13.54 +0.52 (+3.99%)
(As of 11/8/2024 ET)

About Neumora Therapeutics Stock (NASDAQ:NMRA)

Key Stats

Today's Range
$13.00
$13.58
50-Day Range
$10.46
$16.96
52-Week Range
$8.33
$21.00
Volume
1.27 million shs
Average Volume
1.39 million shs
Market Capitalization
$2.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67
Consensus Rating
Moderate Buy

Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
50th Percentile Overall Score

NMRA MarketRank™: 

Neumora Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 572nd out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neumora Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Neumora Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neumora Therapeutics are expected to decrease in the coming year, from ($1.48) to ($1.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neumora Therapeutics is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neumora Therapeutics is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neumora Therapeutics has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Neumora Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.41% of the float of Neumora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neumora Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neumora Therapeutics has recently decreased by 6.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Neumora Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Neumora Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.41% of the float of Neumora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neumora Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neumora Therapeutics has recently decreased by 6.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Neumora Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Neumora Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,390,513.00 in company stock.

  • Percentage Held by Insiders

    26.40% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neumora Therapeutics' insider trading history.
Receive NMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NMRA Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Contrasting Neumora Therapeutics (NMRA) & Its Rivals
Stifel Nicolaus Remains a Buy on Neumora Therapeutics, Inc. (NMRA)
See More Headlines

NMRA Stock Analysis - Frequently Asked Questions

Neumora Therapeutics' stock was trading at $17.05 at the start of the year. Since then, NMRA stock has decreased by 20.6% and is now trading at $13.54.
View the best growth stocks for 2024 here
.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its earnings results on Tuesday, August, 6th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37).

Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.

Top institutional shareholders of Neumora Therapeutics include Auour Investments LLC (0.16%), LMR Partners LLP, Handelsbanken Fonder AB (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Kristina Burow, Robert A Lenz and Joshua Pinto.
View institutional ownership trends
.

Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP).

Company Calendar

Last Earnings
8/06/2024
Today
11/10/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NMRA
Fax
N/A
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.67
High Stock Price Target
$30.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+60.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-235,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.07 per share

Miscellaneous

Free Float
117,781,000
Market Cap
$2.17 billion
Optionable
Optionable
Beta
3.92
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:NMRA) was last updated on 11/10/2024 by MarketBeat.com Staff
From Our Partners